PMID- 28704600
OWN - NLM
STAT- MEDLINE
DCOM- 20190107
LR  - 20220409
IS  - 2151-4658 (Electronic)
IS  - 2151-464X (Print)
IS  - 2151-464X (Linking)
VI  - 70
IP  - 4
DP  - 2018 Apr
TI  - Comparable Rates of Glucocorticoid-Associated Adverse Events in Patients With 
      Polymyalgia Rheumatica and Comorbidities in the General Population.
PG  - 643-647
LID - 10.1002/acr.23320 [doi]
AB  - OBJECTIVE: To investigate the use of glucocorticoids (GCs) and related adverse 
      events (AEs) in a long-term, geographically defined cohort of patients with 
      polymyalgia rheumatica (PMR). METHODS: Using a population-based inception cohort, 
      details of GC therapy were abstracted from medical records of all patients 
      diagnosed with PMR in 2000-2014. Age- and sex-matched comparators without PMR 
      were identified from the same underlying population. Cumulative and daily dosage 
      of GC, rate of disease relapse, occurrence of GC-related AEs, and rate of GC 
      discontinuation were analyzed. RESULTS: The study included 359 patients with PMR 
      and 359 comparators. The median time to taper below 5 mg/day for 6 months was 
      1.44 years (95% confidence interval [95% CI] 1.36-1.62), while the median time to 
      permanent discontinuation was 5.95 years (95% CI 3.37-8.88). The mean +/- SD 
      cumulative dose of GC at 2 and 5 years was 4.0 +/- 3.5 grams and 6.3 +/- 9.8 grams, 
      respectively. The mean +/- SD daily dose of GC at 2 and 5 years was 6.1 +/- 7.6 
      mg/day and 7.2 +/- 9.5 mg/day, respectively. There were no differences in rates of 
      AEs between patients with PMR and comparators for diabetes mellitus, 
      hypertension, hyperlipidemia, or hip, vertebral, or Colles fractures (P > 0.2 for 
      all). Cataracts were more common in patients with PMR than comparators (hazard 
      ratio 1.72 [95% CI 1.23-2.41]). CONCLUSION: Relapse rates in PMR are highest in 
      the early stages of therapy. Despite often protracted therapy, with the exception 
      of cataracts, the rates of studied morbidities linked to GC are not more common 
      in PMR than comparators.
CI  - (c) 2017, American College of Rheumatology.
FAU - Shbeeb, Izzat
AU  - Shbeeb I
AD  - Mayo Clinic College of Medicine, Rochester, Minnesota.
FAU - Challah, Divya
AU  - Challah D
AD  - Mayo Clinic College of Medicine, Rochester, Minnesota.
FAU - Raheel, Shafay
AU  - Raheel S
AD  - Mayo Clinic College of Medicine, Rochester, Minnesota.
FAU - Crowson, Cynthia S
AU  - Crowson CS
AD  - Mayo Clinic College of Medicine, Rochester, Minnesota.
FAU - Matteson, Eric L
AU  - Matteson EL
AD  - Mayo Clinic College of Medicine, Rochester, Minnesota.
LA  - eng
GR  - R01 AG034676/AG/NIA NIH HHS/United States
GR  - UL1 TR000135/TR/NCATS NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, N.I.H., Extramural
DEP - 20180222
PL  - United States
TA  - Arthritis Care Res (Hoboken)
JT  - Arthritis care & research
JID - 101518086
RN  - 0 (Glucocorticoids)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Comorbidity
MH  - Drug Administration Schedule
MH  - Female
MH  - Glucocorticoids/administration & dosage/*adverse effects
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Minnesota/epidemiology
MH  - Polymyalgia Rheumatica/diagnosis/*drug therapy/epidemiology
MH  - Recurrence
MH  - Remission Induction
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Time Factors
MH  - Treatment Outcome
PMC - PMC6475501
MID - NIHMS1022797
EDAT- 2017/07/14 06:00
MHDA- 2019/01/08 06:00
PMCR- 2019/04/20
CRDT- 2017/07/14 06:00
PHST- 2016/11/02 00:00 [received]
PHST- 2017/07/11 00:00 [accepted]
PHST- 2017/07/14 06:00 [pubmed]
PHST- 2019/01/08 06:00 [medline]
PHST- 2017/07/14 06:00 [entrez]
PHST- 2019/04/20 00:00 [pmc-release]
AID - 10.1002/acr.23320 [doi]
PST - ppublish
SO  - Arthritis Care Res (Hoboken). 2018 Apr;70(4):643-647. doi: 10.1002/acr.23320. 
      Epub 2018 Feb 22.